Home / Market News / $ABT
fiscal.ai Corporate Catalyst Impact 55/100 ● negative

Class Action Lawsuit Filed Against Abbott Laboratories Over Glucerna Labeling

Nov 17, 2026, 3:03 AM UTC · Primary ticker $ABT

Abbott Laboratories is facing a class action lawsuit alleging false labeling of its Glucerna nutrition shakes regarding sugar content. The suit claims the products contain allulose, which should be counted as sugar, potentially misleading carb-conscious consumers and impacting product perception and sales.

Abbott Laboratories is being sued in a class action lawsuit alleging that its Glucerna '1g Total Sugars' shakes are falsely labeled because they contain allulose, which plaintiffs claim should be counted as sugar. This matters because it directly challenges the marketing and perceived health benefits of a key product line, potentially leading to reputational damage, legal costs, and a need to relabel products. Abbott is directly affected, facing potential financial penalties and a hit to consumer trust. In the short term, this could create negative sentiment around ABT stock, while long-term implications depend on the lawsuit's outcome and any required product changes. A key risk for traders is the potential for a prolonged legal battle and the broader impact on Abbott's nutrition segment.

$ABT negative Directly targeted by class action lawsuit
$MDLZ neutral Potential broader scrutiny on food labeling
$KHC neutral Potential broader scrutiny on food labeling
$PEP neutral Potential broader scrutiny on food labeling
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.